Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) Announces Six-Month Preliminary Data From EYP-1901...
Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) has released six-month preliminary data from the "Durasert and Vorolanib in Ophthalmology” phase 1 clinical study of EYP-1901 in...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Amarin Corporation plc (NASDAQ:AMRN) Presents VASCEPA® Clinical Study Findings At The...
Amarin Corporation plc (NASDAQ:AMRN) has presented clinical results from the CardioLink-9 Trial, the initial VASCEPA® study data in COVID-19 infected outpatients at...
MAKE IT MODERN
LATEST REVIEWS
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Announces Its Partnership With Persephone...
Ginkgo Bioworks Holdings Inc (NYSE: DNA) has announced partnering with Persephone Biosciences Inc to develop a Bacteroides-based therapy. Bacteroides are a genus of bacteria...
MAKE IT MODERN
PERFORMANCE TRAINING
Pre-Market SPY moves up over 300
Today we are seeing a rally over the weekend in our markets as well as in the markets in Europe and in Asia....
Moderna Inc. (NASDAQ:MRNA) Completes Enrolment In Phase 3 COVE Study For Its mRNA-1273 Vaccine...
Moderna Inc. (NASDAQ:MRNA) has announced that it has finalized the enrolment of 30,000 subjects in the Phase 3 COVE trial of its experimental COVID-19...
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Announce Promising Results Of Cosibelimab in Treating mCSCC
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) has announced interim results of its on-going open-label, multicohort, global Phase 1 clinical study of cosibelimab, its PD-L1 antibody in...
AEterna Zentaris Inc. (NASDAQ: AEZS) Receives a Note of Allowance for AEZS-150
AEterna Zentaris Inc. (NASDAQ: AEZS) announced that the U.S Patent and Trademark Office gave the University of Sheffield, its licensor, an allowance notice after...
Forte Biosciences Inc (NASDAQ:FBRX) Kicks Off Patient Dosing In Clinical Trial Evaluating FB-401 As...
Forte Biosciences Inc (NASDAQ:FBRX) recently announced the commencement of dosing in a clinical trial designed to evaluate FB-401 as a therapy for patients suffering...
MAKE IT MODERN
